About Us
Elusys Therapeutics leverages immune-stimulatory and immune-derived therapies to combat infectious disease. Our anthrax antitoxin obiltoxaximab, licensed as ANTHIM® in the United States and Canada and as NYXTHRACIS® in the Great Britain and the European Union, is a medical countermeasure to mitigate the effect of anthrax exposure after a natural incident or intentional attack. Our mission is to accelerate the development and commercialization of novel biodefense solutions to defend tomorrow today.
Our Partners
![Barda Barda](https://elusys.com/wp-content/uploads/2022/07/barda.png)
![CDC CDC](https://elusys.com/wp-content/uploads/2022/07/cdc-logo.png)
![JPE-CBD JPE-CBD](https://elusys.com/wp-content/uploads/2022/07/jpe-cbd-logo.png)
![NIH NIH](https://elusys.com/wp-content/uploads/2022/07/national-allergy-logo.png)
![DOD DOD](https://elusys.com/wp-content/uploads/2022/07/dod-logo.png)
![Aji-Biopharma Aji-Biopharma](https://elusys.com/wp-content/uploads/2022/07/aji-biopharma.png)
![SFL SFL](https://elusys.com/wp-content/uploads/2022/07/sfl-logo.png)
![Singota Singota](https://elusys.com/wp-content/uploads/2022/07/singota-logo.png)
![Lonza Lonza](https://elusys.com/wp-content/uploads/2022/07/lonza-new.png)
![Scorpius Biomanufacturing Scorpius Biomanufacturing](https://elusys.com/wp-content/uploads/2022/12/Scorpius_Logo_Horizontal.png)